ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc.

ZIOP

ZIOPZIOPHARM Oncology, Inc. US flag

NASDAQ Global Select

0.87

USD

-0.01

- -

208.12MMarket Cap

ZIOPHARM Oncology, Inc.

ZIOP

(NASDAQ Global Select)

Recent

price

0.87

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Kexing Biopharm Co., Ltd. (688136.SS)
Alzinova AB (publ) (ALZ.ST)
Denali Therapeutics Inc. (DNLI)
IBEX Technologies Inc. (IBT.V)
Biovica International AB (publ) (BIOVIC-B.ST)
CStone Pharmaceuticals (CSPHF)
Business: Ziopharm Oncology, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative cancer immunotherapies and precision medicines. The company specializes in gene therapies and cell-based immunotherapy products designed to treat various forms of cancer. Its core products and services include the development of precision medicine platforms such as adoptive cell therapies, gene modulation technologies, and next-generation drug delivery systems. Ziopharm's offerings encompass therapies targeting hematologic malignancies and solid tumors, leveraging proprietary synthetic biology and gene editing technologies. Ziopharm operates primarily in the United States with ongoing clinical trials and collaborations across multiple countries. Founded in 2003 and headquartered in Boston, Massachusetts, the company emphasizes cutting-edge scientific innovation in oncology. In recent major developments, Ziopharm has entered strategic partnerships and alliances to advance its immuno-oncology pipeline, including collaborations with pharmaceutical companies and research institutions. Over the last 1-2 years, the company has expanded its clinical programs and technology platforms, launched new investigational therapies, and secured funding to support late-stage clinical trials and product development. These steps reflect a strategic focus on accelerating the development and commercialization of its gene and cell therapy candidates. Ziopharm Oncology operates within the biopharmaceutical and cancer therapeutics industry, targeting oncologists, healthcare providers, and patients with unmet medical needs in cancer treatment. The company’s business segments focus on immuno-oncology therapies and precision gene medicines. It maintains a robust pipeline of investigational products and actively engages in collaborative research and licensing agreements to enhance its technology base and market reach. As a publicly traded company under the ticker ZIOP, Ziopharm maintains its commitment to innovation in oncology drug development and delivering transformative therapies for cancer patients.

Company News